Abstract
The promise of targeted protein degradation to drug ‘undruggable’ proteins is driving a surge of venture funding and partnerships around this novel therapeutic modality. The promise of targeted protein degradation to drug ‘undruggable’ proteins is driving a surge of venture funding and partnerships around this novel therapeutic modality.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
